Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole

Breast Cancer Research

Volumn 12, Issue 4, 2010, Pages

  Miller, William R ^a,b   Larionov, Alexey ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLINE; ESTROGEN; ESTROGEN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; LETROZOLE; PROTEIN; PROTEIN CDC2; PROTEIN CKS 2; PROTEIN KIAA0101; PROTEIN SERPINA3; PROTEIN TFF1; PROTEIN TFF3; RNA; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; ECHOGRAPHY; FEMALE; GENE EXPRESSION; HUMAN; POSTMENOPAUSE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT THERAPY; BREAST TUMOR; CELL PROLIFERATION; CLINICAL TRIAL; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC HETEROGENEITY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TRIAZOLES;

EID: 78650899317     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2611     Document Type: Article

References (49)

1. Miller WR, Anderson TJ, Iqbal S, Dixon JM. Neoadjuvant Therapy: Prediction of Response. Endocrine Therapy in Breast Cancer 2002, 223-229. New York: Marcel Dekker, Miller WR, Ingle JN.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097, Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
3. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007, 608:1-22. full_text, 17993229.
4. Buzdar AU. Data from the arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003. Clin Cancer Res 2004, 10:355S-361S. 10.1158/1078-0432.CCR-031203, 14734491.
5. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C, . Intergroup Exemestane Study A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1192. 10.1056/NEJMoa040331, 15014181, Intergroup Exemestane Study.
6. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M, . Letrozole Neoadjuvant Breast Cancer Study Group Preoperative treatment of postmenopausal breast cancer patients with letrozole. A randomised double-blind multicentre study. Ann Oncol 2001, 12:1527-1532. 10.1023/A:1013128213451, 11822750, Letrozole Neoadjuvant Breast Cancer Study Group.
7. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802. 10.1056/NEJMoa032312, 14551341.
8. Miller WR. Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab 2004, 18:1-32. 10.1016/S1521-690X(03)00044-7, 14687595.
9. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003, 348:2431-2442. 10.1056/NEJMra023246, 12802030.
10. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002, 20:751-757. 10.1200/JCO.20.3.751, 11821457.
11. Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB, Dixon JM. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol 2009, 27:1382-1387. 10.1200/JCO.2008.16.8849, 19224856.
12. Scherer A, Krause A, Walker JR, Sutton SE, Serón D, Raulf F, Cooke MP. Optimized protocol for linear rna amplification and application to gene expression profiling of human renal biopsies. BioTechniques 2003, 34:546-556.
13. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Research 2003, 31:e15. 10.1093/nar/gng015, 150247, 12582260.
14. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264. 10.1093/biostatistics/4.2.249, 12925520.
15. R Development Core Team R: a language and environment for statistical computing. 2006, Vienna: R Foundation for Statistical Computing, R Development Core Team.
16. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biology 2004, 5:R80. 10.1186/gb-2004-5-10-r80, 545600, 15461798.
17. Gene Expression Omnibus. , http://www.ncbi.nlm.nih.gov/geo/
18. Itoh T, Karlsberg K, Kijima I, Yuan YC, Smith D, Ye J, Chen S. Letrozole-, anastrozole- and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. Mol Cancer Res 2005, 3:203-218.
19. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003, 144:4562-4574. 10.1210/en.2003-0567, 12959972.
20. Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006, 24:1656-1664. 10.1200/JCO.2005.03.2755, 16505416.
21. Lin CY, Ström A, Vega VB, Kong SL, Yeo AL, Thomsen JS, Chan WC, Doray B, Bangarusamy DK, Ramasamy A, Vergara LA, Tang S, Chong A, Bajic VB, Miller LD, Gustafsson JA, Liu ET. Discovery of estrogen receptor α target genes and response elements in breast tumor cells. Genome Biol 2004, 5:R66. 10.1186/gb-2004-5-9-r66, 522873, 15345050.
22. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen S. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004, 64:1522-1533. 10.1158/0008-5472.CAN-03-3326, 14973112.
23. Dressman MA, Walz TM, Lavedan C, Barnes L, Buchholtz S, Kwon I, Ellis MJ, Polymeropoulos MH. Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies. Pharmacogenomics J 2001, 1:135-141.
24. Aitken SC, Lippman ME. Effect of estrogens and antiestrogens on growth-regulatory enzymes in human breast cancer cells in tissue culture. Cancer Res 1985, 45:1611-1620.
25. Foster JS, Wimalasena J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 1996, 10:488-498. 10.1210/me.10.5.488, 8732680.
26. Moggs JG, Murphy TC, Lim FL, Moore DJ, Stuckey R, Antrobus K, Kimber I, Orphanides G. Anti-proliferative effect of estrogen in breast cancer cells that reexpress Erα is mediated by aberrant regulation of cell cycle genes. J Mol Endocrinal 2005, 34:535-551. 10.1677/jme.1.01677, 15821115.
27. Miller WR, Larionov A, Renshaw L, Anderson TJ, White S, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM. Changes in gene expression signatures in breast cancers following neoadjuvant treatment with the aromatase inhibitor, letrozole, by microarray analysis of sequential tumour biopsies. Pharmacogenet Genomics 2007, 17:813-826. 10.1097/FPC.0b013e32820b853a, 17885619.
28. Larionov A, Krause A, Miller W. A standard curve based method for relative real time PCR data processing. BMC Bioinformatics 2005, 6:62. 10.1186/1471-2105-6-62, 1274258, 15780134.
29. Larionov AA, Dixon JM, Krause A, Evans DB, Miller WR. Validation of reference genes for relative real time PCR to study hormone-dependent gene expression in breast cancer biopsies. Breast Cancer Res Treatment 2005, 94 Suppl 1:S253.
30. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, DePaepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3:RESEARCH0034. 10.1186/gb-2002-3-7-research0034, 126239, 12184808.
31. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. Bioinformatics Methods and Protocols: Methods in Molecular Biology 2002, 365-386. Totowa NJ: Humana Press, Krawetz S, Misener S.
32. Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 2006, 94:1051-1056. 10.1038/sj.bjc.6603001, 2361236, 16538221.
33. Carpenter R, Miller WR. Role of aromatase inhibitors in breast cancer. Br J Cancer 2005, 93:S1-S5. 10.1038/sj.bjc.6602688, 2361691, 16100519.
34. Miller WR. Aromatase inhibitors. End Related Cancer 1996, 3:65-79.
35. Lonning PE. Pharmacology and clinical experience with exemestane. Expert Opin Investig Drugs 2000, 9:1897-1905. 10.1517/13543784.9.8.1897, 11060785.
36. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995, 1:1511-1515.
37. Miller WR, Larionov A, Renshaw L, Anderson TJ, White S, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM. Aromatase inhibitors - gene discovery. J Steroid Biochem Mol Biol 2007, 106:130-142. 10.1016/j.jsbmb.2007.05.013, 17616392.
38. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007, 9:R37. 10.1186/bcr1732, 1929101, 17555561.
39. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R, Bieche I. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 2006, 13:1109-1120. 10.1677/erc.1.01120, 17158757.
40. Molloy CA, May FE, Westley BR. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem 2000, 275:12565-12571. 10.1074/jbc.275.17.12565, 10777546.
41. Creighton CJ, Cordero KE, Larios JM, Miller RS, Johnson MD, Chinnaiyan AM, Lippman ME, Rae JM. Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol 2006, 7:R28. 10.1186/gb-2006-7-4-r28, 1557996, 16606439.
42. Stoimenov I, Helleday T. PCNA on the crossroad of cancer. Biochem Soc Trans 2009, 37:605-613. 10.1042/BST0370605, 19442257.
43. Miller WR. Aromatase inhibitors and breast cancer. Minerva Endocrinol 2006, 31:27-46.
44. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004, 11:643-658. 10.1677/erc.1.00776, 15613444.
45. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002, 2:101-112. 10.1038/nrc721, 12635173.
46. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643. 10.1038/nrc2713, 19701242.
47. Dixon JM. Neoadjuvant therapy: surgical perspectives. Endocrine Therapy in Breast Cancer 2002, 197-212. New York: Marcel Dekker, Miller WR, Ingle JN.
48. Dixon JM, Renshaw L, Macaskill EJ, Young O, Murray J, Cameron D, Kerr GR, Evans DB, Miller WR. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 2009, 113:145-151. 10.1007/s10549-008-9915-6, 18264759.
49. Miller WR, Anderson T, Hawkins RA, Keene J, Dixon JM. Neoadjuvant endocrine treatment: the Edinburgh Experience. ESO Scientific Updates; Primary Medical Therapy for Breast Cancer 1999, 4:1-11. Amsterdam: Elsevier, Howell A, Dowsett M.